摘要
目的:探讨莫西沙星治疗慢性阻塞性肺疾病(COPD)合并呼衰对患者肺功能、氧代谢及血清C反应蛋白(CRP)、肌酸激酶(CK)、乳酸脱氢酶(LDH)、中性粒细胞(NBC)水平的影响。方法:选取2018年3月至2020年3月间收治的62例COPD合并呼衰患者为研究对象,采用随机数字表简单随机分为观察组、对照组,各31例。两组患者均接受常规治疗,对照组患者应用硫酸沙丁胺醇雾化吸入治疗,观察组患者应用莫西沙星雾化吸入治疗。对比两组患者治疗前后的肺功能、氧代谢指标及血清CRP、CK、LDH、NBC水平差异及临床疗效。结果:治疗前,两组患者的FVC、FEV1、FEV1/FVC、CaO2、VO2 Max、ERO2、血清CRP、CK、LDH、NBC水平比较差异无统计学意义(P>0.05);治疗后,两组患者的FVC、FEV1、FEV1/FVC、CaO2水平均高于治疗前,且观察组患者升高程度更大,而两组患者的VO2 Max、ERO2、血清CRP、CK、LDH、NBC水平均低于治疗前,且观察组患者降低程度更大,差异具有统计学意义(P<0.05)。两组患者疗效比较,差异具有统计学意义(P<0.05),观察组患者临床疗效总有效率为96.77%,,明显高于对照组患者的80.65%,差异具有统计学意义(P<0.05)。结论:莫西沙星治疗COPD合并呼衰疗效显著,可有效提高患者肺功能、氧代谢水平,并改善患者血清CRP、CK、LDH、NBC水平,值得临床推广。
Objective:To explore the effects of moxifloxacin in the treatment of chronic obstructive pulmonary disease(COPD)patients with respiratory failure on lung function,oxygen metabolism,serum C-reactive protein(CRP),creatine kinase(CK),lactate dehydrogenase(LDH),and neutrophils(NBC)level.Methods:62 COPD patients with respiratory failure admitted between March 2018 and March 2020 were selected as the research objects,and were simply randomly divided into observation group and control group,with 31 cases in each group,using a random number table.Patients in the two groups received conventional treatment.Patients in the control group were treated with aerosol inhalation of salbutamol sulfate,and patients in the observation group were treated with aerosol inhalation of moxifloxacin.The differences in lung function,oxygen metabolism indexes,serum CRP,CK,LDH,and NBC levels before and after treatment were compared between the two groups of patients and the clinical efficacy.Results:Before treatment,there was no significant difference in the levels of FVC,FEV1,FEV1/FVC,CaO2,VO2 Max,ERO2,serum CRP,CK,LDH,and NBC between the two groups of patients(P>0.05);The levels of FVC,FEV1,FEV1/FVC,and CaO2 were higher than before treatment,and the increase in the observation group was greater,while the VO2 Max,ERO2,serum CRP,CK,LDH,and NBC levels of the two groups of patients were lower than before treatment.The degree of reduction in the observation group was greater,and the difference was statistically significant(P<0.05).The difference in efficacy between the two groups of patients was statistically significant(P<0.05).The total effective rate of clinical efficacy in the observation group was 96.77%,which was significantly higher than that of the control group(80.65%).The difference was statistically significant(P<0.05).Conclusion:Moxifloxacin has a significant effect in the treatment of COPD patients complicated with respiratory failure,which can effectively improve patients'lung function,oxygen metabolism,and improve patients'serum CRP,CK,LDH,and NBC levels.It is worthy of clinical promotion.
作者
马菲菲
史亮
MA Feifei;SHI Liang(Shenyang North Theater General Hospital, Liaoning Shenyang 110000, China)
出处
《河北医学》
CAS
2021年第6期896-901,共6页
Hebei Medicine
基金
辽宁省博士启动基金项目,(编号:2020-BS-033)。
关键词
慢性阻塞性肺疾病
莫西沙星
呼吸衰竭
肺功能
氧代谢
Chronic obstructive pulmonary disease
Moxifloxacin
Respiratory failure
Lung function
Oxygen metabolism
